Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 16/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 14/20 | 0.54 |
| ▸ | CCNA1 | P78396 | 14/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 13/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 13/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 12/20 | 0.54 |
| ▸ | CDK9 | P50750 | 2/20 | 0.44 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19670105 | 0.85 | CDK2 (0.55) | CDK2CCNA2CCNA1CDK5CDK5R1 | |
| SCHEMBL21017207 | 0.80 | CDK2 (0.52) | CDK2CCNA2CCNA1CDK5CDK5R1 | |
| SCHEMBL2315371 | 0.79 | CDK2 (0.54) | CDK2CCNA2CCNA1CDK5CDK5R1 | |
| SCHEMBL20542038 | 0.79 | CDK5 (0.41) | CDK2CCNA2CCNA1CDK5CDK5R1 | |
| SCHEMBL30579367 | 0.79 | CDK5 (0.41) | CDK2CCNA2CCNA1CDK5CDK5R1 | |
| SCHEMBL25308297 | 0.76 | CCNK (0.64) | CDK2CCNA2CCNA1CDK5CDK5R1 | |
| SCHEMBL30518535 | 0.76 | CCNK (0.64) | CDK2CCNA2CCNA1CDK5CDK5R1 | |
| SCHEMBL21016422 | 0.75 | CDK2 (0.48) | CDK2CCNA2CCNA1CDK5CDK5R1 | |
| SCHEMBL2312183 | 0.75 | AHR (0.43) | CDK2CCNA2CCNA1CDK5CDK5R1 | |
| SCHEMBL2318356 | 0.75 | AHR (0.51) | CDK2CCNA2CCNA1CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3524604-B1 | EXPANDED HEMATOPOIETIC STEM CELLS FROM CORD BLOOD AND THEIR THERAPEUTIC USE | NOVARTIS AG (CH) | 2023-03-29 | — | — | EP | disclosed |
| US-20210187033-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2021-06-24 | — | — | US | disclosed |
| EP-3524604-A1 | EXPANDED HEMATOPOIETIC STEM CELLS FROM CORD BLOOD AND THEIR THERAPEUTIC USE | Novartis AG (CH) | 2019-08-14 | — | — | EP | disclosed |
| EP-2350078-B1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2019-04-17 | — | — | EP | disclosed |
| US-20170239296-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-9580426-B2 | Compounds that expand hematopoietic stem cells | NOVARTIS AG (CH) | 2017-02-28 | — | — | US | disclosed |
| US-8927281-B2 | Method for expanding hematopoietic stem cells | IRM LLC (BM) | 2015-01-06 | — | — | US | disclosed |
| CN-102203096-B | Compounds that expand hematopoietic stem cells | IRM LLC | 2014-09-17 | — | — | CN | disclosed |
| WO-2014138485-A1 | EX VIVO PRODUCTION OF PLATELETS FROM HEMATOPOIETIC STEM CELLS AND THE PRODUCT THEREOF | IRM LLC (BM) | 2014-09-12 | — | — | WO | disclosed |
| US-20140114070-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-04-24 | — | — | US | disclosed |
| CN-102203096-A | Compounds that expand hematopoietic stem cells | IRM LLC | 2011-09-28 | — | — | CN | disclosed |
| EP-2350078-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2011-08-03 | — | — | EP | disclosed |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
| WO-2010059401-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239296-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | CDK2 3659/4885CCNA2 2265/4885CCNA1 2504/4885 |
| US-20210187033-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | CDK2 3659/4885CCNA2 2265/4885CCNA1 2504/4885 |
| US-20140114070-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | CDK2 3659/4885CCNA2 2265/4885CCNA1 2504/4885 |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | CDK2 3659/4885CCNA2 2265/4885CCNA1 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.